Risk for Secondary Cancer Higher for Primary Cutaneous B-Cell Lymphoma
Patients with pCBCL have increased risk for second primary prostate cancer and lymphoma
By Dermsquared Editorial Team | May 01, 2025
WEDNESDAY, April 30, 2025 (HealthDay News) -- Patients with primary cutaneous B-cell lymphomas (pCBCL) have an increased risk for secondary hematologic and prostate cancers, according to a research letter published online April 30 in JAMA Dermatology.
Vrusha K. Shah, M.P.H., from the University of Pittsburgh School of Medicine, and colleagues examined second primary solid and hematologic cancer risk and demographic factors in patients with pCBCL in a U.S. patient cohort. Data were obtained from 17 Surveillance, Epidemiology, and End Results cancer registries.
The researchers found that among 3,757 patients with pCBCL, 343 (9.1 percent) had secondary cancers. Of these, 65.0 and 32.4 percent had solid tumor cancers and hematologic cancers, respectively. Patients had an elevated risk for prostate cancer and lymphoma. Compared with those without, patients with secondary cancers often were of White race (90.7 versus 82.5 percent), were aged 50 to 74 years (68.2 versus 48.4 percent), and had stage I (62.4 versus 47.5 percent) or stage II (5.5 versus 3.4 percent) lymphoma. Latency to secondary cancers was shorter for women than men (9.9 versus 12.2 years).
"Patients with pCBCL have increased second primary hematologic and prostate cancer risk," the authors write. "Future studies should consider patient factors associated with secondary cancers when developing screening guidelines."